Liquid Dose Featured Articles

  1. The Future Of Continuous Is Integrated Manufacturing: The 4 Misconceptions About A Lean Process 6/2/2026

    Pharmaceutical continuous manufacturing is an enabler of better manufacturing, but only when implemented with intention.

  2. Drug Substance To Fill-Finish Handoff: What Sponsors Need To Know 5/14/2026

    Effective drug substance handoff to fill-finish manufacturing depends on early collaboration, clear communication, and proactive planning to reduce risks, ensure quality, and maintain timelines.

  3. Gaining An Edge In GLP-1 Production 5/5/2026

    The shortage-driven production of GLP-1 drugs of the past few years is giving way to a long-term operation model characterized by digital enablement and supply chain resilience.

  4. How Generic Pharma Manufacturers Can Rebuild Margins Inside The Four Walls 5/4/2026

    The pricing dynamics for generic drugs turns formerly attractive products into high-volume, low-margin commodities. Lean and Six Sigma in four key areas can unlock efficiencies.

  5. Advancing TIDES Manufacturing Through Biocatalysis And Flow Technologies 4/17/2026

    Integrated biocatalysis and continuous processing are reshaping therapeutic manufacturing, enabling faster scale‑up, greater efficiency, and lower costs as peptides and oligonucleotides meet demands.

  6. U.S. Pharma Tariffs And MFN Become Law After April 2 Update 4/15/2026

    Beginning July 31, 2026, a U.S. pharmaceutical tariff will apply to patented products and their APIs, beginning with large companies. Beroe Inc.'s Mathini Ilancheran breaks down the tariff's impact, explores its risks, and proposes five procurement strategies to addressing them.

  7. How Asia and Europe Are Reshaping Biologics Manufacturing 4/9/2026

    As biologics manufacturing globalizes, companies must balance cost, capacity, risk, and control when choosing between European and Asian supply bases for clinical and commercial success.

  8. Stability Issues Unique To Liquid Injectables And How To Avoid Them 3/23/2026

    Liquid injectables face stability risks like oxidation, hydrolysis, aggregation, temperature shifts, and packaging effects, requiring early, rigorous formulation and process controls.

  9. Organic Impurities: New Draft ICH Q3E Guidance For Leachables And Extractables 3/17/2026

    A new draft guidance document from ICH, issued jointly with the EMA, adopts the position that the assessment of leachables and extractables requires a holistic framework for risk evaluation.

  10. The Challenges Of Developing Combination Products 3/13/2026

    Examine the regulatory complexity of combination products and learn how holistic development strategies, early equipment decisions, and representative clinical supply reduce risk and costs.